Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189670
Status:
COMPLETED
Last Update Posted:
2005-09-19
First Post:
2005-09-12
Brief Title:
Randomized Phase II Trial of Dose Dense Docetaxel in N Breast Cancer
Sponsor:
Association Européenne de Recherche en Oncologie
Organization:
Association Européenne de Recherche en Oncologie
Study Overview
Official Title:
A Phase II Randomized Trial of 6 TEC Every 3 Weeks Versus 4 EC Followed by 4 Taxotere Every 2 Weeks Versus 4 Taxotere Followed by 4 EC Every 2 Weeks in Node Positive Breast Cancer
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To screen a dose-dense arm to be used in a future large scale phase III trial Primary endpoint is safety secondary endpoints are disease free survival and overall survival A total of 100 patients were included
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None